众生药业 (002317.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

50.6x

EV/EBITDA

48.8x

Market Cap

CNY 21.54B

MomentumView details →

1D Return

−3.17%

YTD Return

+29.82%

RSI (14)

41.8

ValuationView details →

P/E (Fwd)

50.6x

EV/EBITDA

48.8x

Market Cap

CNY 21.54B

RSI (14)

41.8

MomentumView details →

1D Return

−3.17%

YTD Return

+29.82%

ProfitabilityView details →

Gross Margin

56.29%

Net Margin

11.66%

EBITDA Margin

16.78%

ROE (TTM)

7.04%

ROA (TTM)

5.48%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

+2.12%

EPS YoY

+207.72%

FCF YoY

+8.86%

Revenue CAGR 3Y

−1.95%

EPS CAGR 3Y

−6.21%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.01

EPS Surprise

−86.03%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.10

Avg Surprise (4Q)

−86.03%

Rev Surprise

−26.25%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.14x

Quick Ratio

3.71x

Div Yield

0.81%

Div Rate

CNY 0.20

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

2.51B

Net Income (TTM)

292.97M

Op. CF (TTM)

475.35M

Next earningsNov 3, 2026 →

Latest newsMore news →

Zhongsheng Pharmaceutical provided a joint liability guarantee of 200 million yuan for its wholly-owned subsidiary Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd. for a comprehensive credit line from Bank of Communications Dongguan Branch.10h ago

Zhongsheng Pharmaceutical received approval from China's National Medical Products Administration to add a 0.2g specification of its fenofibrate capsules, deemed consistent with generic drug quality and efficacy.10h ago

Similar companies

宏达电子300726.SZ 航天发展000547.SZ 吉林敖东000623.SZ 常山药业300255.SZ 乐普医疗300003.SZ 万丰奥威002085.SZ Find similar companies →

Latest newsMore news →

Zhongsheng Pharmaceutical provided a joint liability guarantee of 200 million yuan for its wholly-owned subsidiary Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd. for a comprehensive credit line from Bank of Communications Dongguan Branch.10h ago Zhongsheng Pharmaceutical received approval from China's National Medical Products Administration to add a 0.2g specification of its fenofibrate capsules, deemed consistent with generic drug quality and efficacy.10h ago